Therapy naive | Squamous cell carcinoma of lung TNM clinical staging | Squamous cell carcinoma of lung Inappropriate Radical therapy | Measurable lesion Quantity
Item
previously untreated, histological documented stage iiib (not amenable for radical regional therapy) or stage iv squamous cell carcinoma of lung. at least one measurable lesion as defined by recist criteria.
boolean
C0919936 (UMLS CUI [1])
C0149782 (UMLS CUI [2,1])
C3258246 (UMLS CUI [2,2])
C0149782 (UMLS CUI [3,1])
C1548788 (UMLS CUI [3,2])
C0260176 (UMLS CUI [3,3])
C1513041 (UMLS CUI [4,1])
C1265611 (UMLS CUI [4,2])
Age
Item
at least 18 years of age.
boolean
C0001779 (UMLS CUI [1])
ECOG performance status
Item
ecog ps 0~1
boolean
C1520224 (UMLS CUI [1])
History of cancer Absent | Exception Carcinoma in situ of uterine cervix Cured | Exception Basal cell carcinoma Cured | Exception Superficial carcinoma of urinary bladder Cured | Neoadjuvant Chemotherapy | Chemotherapy, Adjuvant | Recurrent disease | Status post Neoadjuvant Chemotherapy Discontinued | Status post Adjuvant Chemotherapy Discontinued
Item
patients have no previously malignant tumor history except cured cervical carcinoma in situ, basal cell carcinoma or superficial bladder cancer. patients are also eligible if they have received a chemotherapy regimen as neoadjuvant or adjuvant chemotherapy and the disease recurred over 12 months since the finishing of neoadjuvant or adjuvant chemotherapy.
boolean
C0455471 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0851140 (UMLS CUI [2,2])
C1880198 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0007117 (UMLS CUI [3,2])
C1880198 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C1336527 (UMLS CUI [4,2])
C1880198 (UMLS CUI [4,3])
C0600558 (UMLS CUI [5,1])
C3665472 (UMLS CUI [5,2])
C0085533 (UMLS CUI [6])
C0277556 (UMLS CUI [7])
C0231290 (UMLS CUI [8,1])
C0600558 (UMLS CUI [8,2])
C3665472 (UMLS CUI [8,3])
C1444662 (UMLS CUI [8,4])
C0231290 (UMLS CUI [9,1])
C0085533 (UMLS CUI [9,2])
C1444662 (UMLS CUI [9,3])
Neutrophil count | Hemoglobin measurement | Platelet Count measurement
Item
neutrophil ≥ 1.5 x 109 /l, hemoglobin > 90 g/l, platelet count > 100x109/l.
boolean
C0200633 (UMLS CUI [1])
C0518015 (UMLS CUI [2])
C0032181 (UMLS CUI [3])
Serum total bilirubin measurement | Alanine aminotransferase measurement | Aspartate aminotransferase measurement | Secondary malignant neoplasm of liver Absent | Secondary malignant neoplasm of liver Present | Creatinine measurement, serum
Item
total bilirubin ≤ 1.5 x upper limit of normal. alt and ast < 2.5 x upper limit of normal without liver metastasis, alt and ast < 5 x upper limit of normal with liver metastasis. serum creatinine < 1.5 x upper limit of normal.
boolean
C1278039 (UMLS CUI [1])
C0201836 (UMLS CUI [2])
C0201899 (UMLS CUI [3])
C0494165 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
C0494165 (UMLS CUI [5,1])
C0150312 (UMLS CUI [5,2])
C0201976 (UMLS CUI [6])
Gender | Urine pregnancy test negative
Item
urine pregnancy test is negative for woman.
boolean
C0079399 (UMLS CUI [1])
C0430057 (UMLS CUI [2])
Life Expectancy
Item
estimated life expectancy is at least 3 months.
boolean
C0023671 (UMLS CUI [1])
Protocol Compliance
Item
patient comply with the clinical trial protocal.
boolean
C0525058 (UMLS CUI [1])
Informed Consent
Item
informed consent must be signed.
boolean
C0021430 (UMLS CUI [1])
Cancer treatment Other
Item
patients who are currently undergoing other anti-tumor therapy.
boolean
C0920425 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
Study Subject Participation Status
Item
patients who was enrolled in any other clinical trial within 4 weeks of study entry.
boolean
C2348568 (UMLS CUI [1])
Physical Examination Finding Suspicious | Laboratory test finding Suspicious | Disease Investigational New Drugs Contraindicated | Condition Investigational New Drugs Contraindicated | Disease Treatment At risk | Condition Treatment At risk
Item
any physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of any study medication or render the subject at high risk from treatment.
boolean
C0031809 (UMLS CUI [1,1])
C0243095 (UMLS CUI [1,2])
C0750493 (UMLS CUI [1,3])
C0587081 (UMLS CUI [2,1])
C0750493 (UMLS CUI [2,2])
C0012634 (UMLS CUI [3,1])
C0013230 (UMLS CUI [3,2])
C1444657 (UMLS CUI [3,3])
C0348080 (UMLS CUI [4,1])
C0013230 (UMLS CUI [4,2])
C1444657 (UMLS CUI [4,3])
C0012634 (UMLS CUI [5,1])
C0087111 (UMLS CUI [5,2])
C1444641 (UMLS CUI [5,3])
C0348080 (UMLS CUI [6,1])
C0087111 (UMLS CUI [6,2])
C1444641 (UMLS CUI [6,3])
Central Nervous System Neoplasms | CNS metastases
Item
central nervous system (cns) tumor or metastatic tumor.
boolean
C0085136 (UMLS CUI [1])
C0686377 (UMLS CUI [2])
Serious mental illness
Item
serious mental disorder.
boolean
C3841614 (UMLS CUI [1])
Other Coding | Agnosia Mild Serious
Item
serious dysgnosia.
boolean
C3846158 (UMLS CUI [1])
C0001816 (UMLS CUI [2,1])
C2945599 (UMLS CUI [2,2])
C0205404 (UMLS CUI [2,3])
Comorbidity Serious
Item
other serious comorbidity.
boolean
C0009488 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
Substance Dependence
Item
alcohol or drug dependence.
boolean
C0038580 (UMLS CUI [1])
Hypersensitivity Investigational New Drugs
Item
previously allergic to drugs used in the study.
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])